الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 76 |  |  |
| | | from | 76 | | |
Abstract
Introduction of DAAs revolutionized CHC treatment; however the limited treatment failure is still challenging especially in those who failed response after NS5A-based regimen. In addition, the limited availability of some recently approved DAAs in some countries (as in Egyptian situation) augments this challenge.In Egypt; the NCCVH recommended treatment of patients who failed response to SOF/DCV-based regimens with a combination of SOF plus OBV/PTV/r ±RBV, or SOF/SMV/DCV±RBV for 12 or 24 weeks according to RBV eligibility. This prospective study aimed at assessment of the efficacy and tolerability of the two regimens recommended by the Egyptian NCCVH for treatment of CHC patients who failed response after SOF/DCV-based regimens. It was conducted on 104 consecutive CHC patients who failed response to SOF/DCV-based regimens and attended New Cairo viral hepatitis treatment center in Cairo within the period between March to November 2018.Patients were allocated to one of the two regimens by consecutive randomization: group A included the first 54 patients and received a combination of SOF plus OBV/PTV/r and RBV for 12 weeks, group B included the next 50 patients and received a combination of SOF/SMV/DCV and RBV for 12 weeks.The demographic and basal characteristics were matching between both groups with no significant differences regarding the previous unsuccessful DAA regimen. Treatment efficacy was assessed by achievement of SVR, defined as undetectable HCV RNA by PCR at 12 weeks after end of treatment. Achieved SVR12 rates were excellent with no statistically significant difference between both study groups, SVR12 was 94.4% (51/54 patients) and 96% (48/50 patients) in group A and group B respectively.